Hematological abnormalities in stroke

Handbook of Cerebrovascular Diseases, Second Edition, Revised and Expanded

Volumn , Issue , 2004, Pages 713-741

  Coull, Bruce M ^a   Olson, Scott ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27644586277     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (266)

1. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke 1990; 21(8):1111–1121
2. del Zoppo GJ, Mori E. Hematologic causes of intracerebral hemorrhage and their treatment. Neurosurg Clin North Am 1992; 3:637–658
3. Eyster MR, Gill FM, Blatt PM, Hilgartner MW, Ballard JO, Kinney TR. Central nervous system bleeding in hemophiliacs. Blood 1978; 51:1179–1188
4. Andes WA, Wulff K, Smith WB. Head trauma in hemophilia. A prospective study. Arch Intern Med 1984; 144:1981–1983
5. Gebel JM, Broderick JP. Intracerebral hemorrhage. Neurol Clin 2000; 18:419–438
6. Earley CJ, Kittner SJ, Feeser BR, Gardner J, Epstein A, Wozniak MA, Wityk R, Sterm BJ, Price TR, Macko RF, Johnson C, Sloan MA, Buchholz D. Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. Neurology 1998; 51:169–176
7. Dahlback B. Blood coagulation. Lancet 2000; 355:1627–1632
8. Lusher JM. Factor VIII inhibitors. Etiology, characterization, natural history, and management. Ann NY Acad Sci 1987; 509:89–102
9. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150:19–29
10. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147:1077–1081
11. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemostasis 1981; 45:200–203
12. Handley DA, Lawrence JR. Factor-IX deficiency in the nephrotic syndrome. Lancet 1967; 1:1079–1081
13. Giroud M, Lemesle M, Madinier G, Manceau E, Osseby GV, Dumas R. Stroke in children under 16 years of age. Clinical and etiological difference with adults. Acta Neurol Scand 1997; 96:401–406
14. Federici A, Mannucci PM, Minetti D, Sina C, Villani R, Zavanone M. Intracranial bleeding in haemophilia. A study of eleven cases. J Neurosurg Sci 1983; 27:31–35
15. DeBehnke DJ, Angelos MG. Intracranial hemorrhage and hemophilia: case report and management guidelines. J Emerg Med 1990; 8:423–427
16. Andes WA, Wulff K. Intracranial hemorrhage in hemophiliacs with AIDS. Thromb Haemostasis 1990; 63:326
17. Rodeghiero F. Von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 8:292–300
18. Lozier JN, High KA. Molecular basis of hemophilia. Hematol Pathol 1990; 4:1–26
19. Bowie EJ. Von Willebrand’s disease. Clinical picture, diagnosis, and treatment. Clin Lab Med 1984; 4:303–317
20. Osenbach RK, Loftus CM, Menezes AH, Biller J, Tannous R, Yuh WT. Management of intraventricular haemorrhage secondary to ruptured arteriovenous malformation in a child with von Willebrand’s disease. J Neurol Neurosurg Psychiatry 1989; 52:1452–1454
21. Almaani WS, Awidi AS. Spontaneous intracranial hemorrhage secondary to von Willebrand’s disease. Surg Neurol 1986; 26:457–460
22. Woerner SJ, Abildgaard CF, French BN. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics 1981; 67:453–460
23. Walker J, Walker W. Idiopathic thrombocytopenia, initial illness and long term follow-up. Arch Dis Child 1961; 36:649–657
24. Lilleyman JS. Idiopathic thrombocytopenic purpura—where do we stand? Arch Dis Child 1984; 59:701–703
25. Hoyle C, Darbyshire P, Eden OB. Idiopathic thrombocytopenia in childhood. Edinburgh experience 1962–82. Scott Med J 1986; 31:174–179
26. DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy. Am J Med 1980; 69:430–442
27. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471–1477
28. Vernon SM. Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. Cardiol Clin 2001; 19:235–252
29. Qureshi AI, Suri MF, Ali Z, Kim SH, Lanzino G, Fessler RD, Ringer AJ, Buterman LR, Hopkins LN. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery 2002; 50:466–473
30. Trivedi SM, Shani J, Hollander G. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro). J Invasive Cardiol 2002; 14:423–425
31. Armstrong PW, Mant MJ. Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. Eur Heart J 1995; 16(suppl L):75–80
32. Bates ER. Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes. Semin Thromb Hemostasis 1997; 23:575–581
33. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119(1 suppl):108S-121S
34. Moonis M, Fisher M. Considering the role of heparin and low-molecular-weight heparins in acute ischemic stroke. Stroke 2002; 33:1927–1933
35. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581–1587
36. Sloan MA, Price TR, Petito CK, Randall AM, Solomon RE, Terrin ML, Gore J, Collen D, Kleiman N, Feit F, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995; 45:649–658
37. Schroder R. Intravenous thrombolysis in acute myocardial infarct. Z Kardiol 1986; 75(suppl 5):93–100
38. ISIS-3. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339:753–770
39. Baker WF Jr. Clinical aspects of disseminated intravascular coagulation: a clinician’s point of view. Semin Thromb Hemostasis 1989; 15:1–57
40. Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemostasis 1978; 39:122–134
41. Schwartzman RJ, Hill JB. Neurologic complications of disseminated intravascular coagulation. Neurology 1982; 32:791–797
42. Morimatsu M, Shirouzu K, Irie K, Tokunaga O, Sasaguri Y. Gross and microscopic characteristics of stomach cancer with microangiopathic hemolytic anemia and/or disseminated intravascular coagulopathy. Acta Pathol Japon 1985; 35:809–822
43. Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56:1–37
44. Al Mondhiry H. Disseminated intravascular coagulation: experience in a major cancer center. Thromb Diath Haemorrhagica 1975; 34:181–193
45. Graus F, Rogers LR, Posner B JB. Cerebrovascular complications in patients with cancer. Medicine 1985; 64:16–35
46. Amico L, Caplan LR, Thomas C. Cerebrovascular complications of mucinous cancers. Neurology 1989; 39:522–526
47. Biller J, Challa VR, Toole JF, Howard VJ. Nonbacterial thrombotic endocarditis. A neurologic perspective of clinicopathologic correlations of 99 patients. Arch Neurol 1982; 39:95–98
48. Kwaan HC. Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol 1987; 24:71–81
49. Collins RC, Al Mondhiry H, Chernik NL, Posner JB. Neurologic manifestations of intravascular coagulation in patients with cancer. A clinicopathologic analysis of 12 cases. Neurology 1975; 25:795–806
50. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83:3460–3464
51. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300:729–735
52. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813–1818
53. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001; 89:1–2
54. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, Muller W, Sandman W, Stoll G. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001; 32:850–854
55. Bertina RM. Hereditary protein S deficiency. Haemostasis 1985; 15:241–246
56. Comp PC. Laboratory evaluation of protein S status. Semin Thromb Hemostasis 1990; 16:177–181
57. Comp PC. Hereditary disorders predisposing to thrombosis. Prog Hemostasis Thromb 1986; 8:71–102
58. Ernerudh J, Olsson JE, von Schenck H. Antithrombin-III deficiency in ischemic stroke. Stroke 1990; 21:967
59. Mayer SA, Sacco RL, Hurlet-Jensen A, Shi T, MohrP JP. Free protein S deficiency in acute ischemic stroke. A case-control study. Stroke 1993; 24:224–227
60. Tosetto A, Ruggeri M, Castaman G, Rodeghiero F. Inherited abnormalities of blood coagulation in juvenile stroke. A case-control study. Blood Coagulation Fibrinolysis 1997; 8:397–402
61. De Lucia D, d’Alessio D, Pezzella S, Maisto G, Di Mauro C, Marotta R, Del Giudice V, Iacoviello L. A hypercoagulable state in activated protein C resistant patients with ischemic stroke. Int J Clin Lab Res 1998; 28:74–75
62. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis—a review of 38 cases. Stroke 1985; 16:199–213
63. Cros D, Comp PC, Beltran G, Gum G. Superior sagittal sinus thrombosis in a patient with protein S deficiency. Stroke 1990; 21:633–636
64. Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediat 1987; 111:562–564
65. Mannucci PM, Tripodi A, Bertina RM. protein S deficiency associated with “juvenile” arterial and venous thromboses. Thromb Haemostasis 1986; 55:440
66. Wintzen AR, Broekmans AW, Bertina RM, Briet E, Briet PE, Zecha A, Vielvoye GJ, Bots GT. Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for “spontaneous” cerebral venous thrombosis. Br Med J Clin Res 1985; 290:350–352
67. Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke 1990; 21:1077–1080
68. Engesser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106:677–682
69. Smith DB, Ens GE. Protein C deficiency: a cause of amaurosis fugax? J Neurol Neurosurg Psychiatry 1987; 50:361–362
70. D’Angelo A, Vigano-D’Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988; 81:1445–1454
71. High KA. Antithrombin III, protein C, and protein S Naturally occurring anticoagulant proteins. Arch Pathol Lab Med 1988; 112:28–36
72. Kessler CM, Strickland DK. Protein C and protein S clinical perspectives. Clin Chim Acta 1987; 170:25–36
73. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32:1793–1799
74. Chancellor AM, Glasgow GL, Ockelford PA, Johns A, Smith J. Etiology, prognosis, and hemostatic function after cerebral infarction in young adults. Stroke 1989; 20:477–482
75. Mettinger KL, Nyman D, Kjellin KG, Siden A, Soderstrom CE. Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease: a study of stroke before 55. J Neurol Sci 1979; 41:31–38
76. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100:736–742
77. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 126:1281–1295
78. Dang CV, Bell WR, Shuman M. The normal and morbid biology of fibrinogen. Am J Med 1989; 87:567–576
79. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126:1387–1390
80. Dale BM, Purdie GH, Rischbieth RH. Fibrinogen depletion with sodium valproate. Lancet 1978; 1:1316–1317
81. Di Minno G, Martinez J, Cirillo F, Cerbone AM, Silver MJ, Colucci M, Margaglione M, Tauro R, Semeraro N, Quattrone A, et al. A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin adsorbing capacity of fibrin(ogen). Arterioscler Thromb 1991; 11:785–796
82. Carrell N, Gabriel DA, Blatt PM, Carr ME, McDonagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 1983; 62:439–447
83. Rodgers GM, Shuman MA. Congenital thrombotic disorders. Am J Hematol 1986; 21:419–430
84. Mudd SH, Levy HL, Skouby F. Disorders of transsulfuration. In: Scriver C, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989:693–734
85. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1–31
86. Cacciari E, Salardi S. Clinical and laboratory features of homocystinuria. Haemostasis 1989; 19(suppl 1):10–13
87. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:709–715
88. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombophilia. Arch Pathol Lab Med 2002; 126:1367–1375
89. Homocysteine SC. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. JAMA 2002; 288:2015–2022
90. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79:1180–1188
91. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia—a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984; 15:1012–1016
92. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21:572–576
93. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407–413
94. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72:324–332
95. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069–1075
96. Mudd SH, Havlik R, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet 1981; 33:883–893
97. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149–1155
98. Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Kojima K, Hackeng TM, Greengard JS. Activated protein C resistance: molecular mechanisms. Thromb Haemostasis 1995; 74:444–448
99. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000; 31:3067–3078
100. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31:1283–1288
101. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996; 27:44–48
102. Austin HCM. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002; 33:2762–2768
103. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99:999–1004
104. Feinberg WM, Bruck DC, Ring ME, Corrigan JJ JJ. Hemostatic markers in acute stroke. Stroke 1989; 20:592–597
105. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47:1075–1079
106. D’Angelo A, Landi G, Vigano’D’Angelo S, Nobile OE, Boccardi E, Candelise L, Mannucci PM. Protein C in acute stroke. Stroke 1988; 19:579–583
107. Landi G, D’Angelo A, Boccardi E, Candelise L, Mannucci PM, Nobile OE, Morabito A. Hypercoagulability in acute stroke: prognostic signifance. Neurology 1987; 37:1667–1671
108. Seino YI. Angiotensin-converting enzyme gene polymorphism and plasminogen activator inhibitor 1 levels in subjects with cerebral infarction. J Thromb Thrombolysis 1998; 5:263–267
109. Nowak-Gottl U, Strater R, Kosch A, von Eckardstein A, Schobess R, Luigs P, Mabel P, Vielhaber H, Kurnik K, Junker R. The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group. Eur J Haematol 2001; 66:57–62
110. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343:940–943
111. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscl Thromb Vasc Biol 1997; 17:3321–3325
112. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31:26–32
113. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelete glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31:1628–1633
114. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95:586–591
115. Weih M, Mehraein S, Valdueza JM, Einhaupl KM, Vetter B, Kulozik AE. Coincidence of factor V Leiden mutation and a mutation in the prothrombin gene at position 20210 in a patient with puerperal cerebral venous thrombosis. Stroke 1998; 29:1739–1740
116. Larsson J, Hillarp A. The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PlA2 in patients with central retinal vein occlusion. Throm Res 1999; 96:323–327
117. Griffin JH, Deguchi H, Fernandez JA. Causes of thrombophilia yet to be discovered: a personal view. Haemostasis 2000; 30(suppl 2):26–33
118. Liu J, Hutzler M, Li C, Petchet L. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): the new thinking. J Thromb Thrombolysis 2001; 11:261–272
119. Silverstein A. Thrombotic thrombocytopenic purpura. The initial neurologic manifestations. Arch Neurol 1968; 18:358–362
120. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56:191–207
121. Ben Yehuda D, Rose M, Michaeli Y, Eldor A. Permanent neurological complications in patients with thrombotic thrombocytopenic purpura. Am J Hematol 1988; 29:74–78
122. Moake JL. Moschcowitz, multimers, and metalloprotease. N Engl J Med 1998; 339:1629–1631
123. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585–1594
124. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578–1584
125. Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91:2839–2846
126. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Safety 1998; 19:89–98
127. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Safety 2001; 24:491–501
128. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Medic 1991; 325:398–403
129. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325:393–397
130. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339:303–305
131. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266:2459–2465
132. Jurgens G, Koltringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology 1987; 37:513–515
133. Woo J, Lau E, Lam CW, Kay R, Teoh R, Wong HY, Prall WY, Kreel L, Nicholls MG. Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke 1991; 22:203–208
134. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17:942–945
135. Misirli H, Somay G, Ozbal N, Yasar EN. Relation of lipid and lipoprotein(a) to ischaemic stroke. J Clin Neurosci 2002; 9:127–132
136. Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G. Lipo-protein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993; 13:826–833
137. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH. Liporotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular diseae. Stroke 1995; 26:1841–1848
138. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm E. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9–19
139. Ridker PM, Stampfer MJ, Henneckens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273:1269–1273
140. Hachinski V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, Spence JD, Doig G, Wolfe BM. Lipids and stroke: a paradox resolved. Arch Neurol 1996; 53:303–308
141. George JN. Platelets. Lancet 2000; 355:1531–1539
142. Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med 1999; 4:165–172
143. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25:2331–2336
144. Godal HC. Report of the International Committee on Thrombosis and Haemostasis. Thrombocytopenia and heparin. Thromb Haemostasis 1980; 43:222–224
145. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330–1335
146. Kappers-Klunne MC, Boon DM, Hop WC, Michiels JJ, Stibbe J, van der Zwaan C, Koudstaal PJ, van Vliet JJ. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol 1997; 96:442–446
147. Pohl C, Harbrecht U, Greinacher A, Theuerkauf I, Biniek R, Hanfland P, Klockgether T. Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Neurology 2000; 54:1240–1245
148. Atkinson JL, Sundt TM Jr, Kazmier FJ, Bowie EJ, Whisnant JP. Heparin-induced thrombocytopenia and thrombosis in ischemic stroke. Mayo Clin Proc 1988; 63:353–361
149. Rogers LA. Postendarterectomy heparin-induced thrombocytopenia. Case report. J Neurosurg 1988; 69:632–634
150. Kyritsis A, Williams EC, Schutta HS. Cerebral venous thrombosis due to heparin-induced thrombocytopenia. Stroke 1990; 21:1503–1505
151. Warkentin TE, Hirte HW, Anderson DR, Wilson WE, O’Connell GJ, Lo RC. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994; 97:489–491
152. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemostasis 1998; 79:1–7
153. Pfueller SL, David R, Firkin BG, Bilston RA, Cortizo WF, Raines G. Platelet aggregating IgG antibody to platelet surface glycoproteins associated with thrombosis and thrombocytopenia. Br J Haematol 1990; 74:336–341
154. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73:235–240
155. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemostasis 1992; 68:95–96
156. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72:925–930
157. Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdaal NA, Kiefel V, van de Winkel JG, Greinacher A. Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 1998; 92:1526–1531
158. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Potzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73–80
159. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Potzsch B, Luz M. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999; 100:587–593
160. Chen JL. Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. Heart Dis 2001; 3:189–198
161. Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001; 35:440–451
162. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126:1424–1429
163. Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun 1988; 155:1001–1007
164. McNeil HP, Chesterman CN, Krilis SA. Binding specificity of lupus anticoagulants and anticardiolipin antibodies. Thromb Res 1988; 52(6):609–619
165. Levine SR, Jacobs BS. 2001: A prospective, seasonal odyssey into antiphospholipid protein antibodies. Stroke 2001; 32:1699–1700
166. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86:3083–3089
167. McIntyre JA, Wagenknecht DR, Sugi T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection—an overview. Am J Reprod Immunol (Copenhagen) 1997; 37:101–110
168. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336:177–178
169. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:1544–1547
170. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001; 32:1701–1706
171. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993; 43:2069–2073
172. Lockshin MD. Antiphospholipid antibody syndrome. JAMA 1992; 268:1451–1453
173. Harris EN. Serological detection of antiphospholipid antibodies. Stroke 1992; 23(2 suppl):13–16
174. Sokol DK, McIntyre JA, Short RA, Gutt J, Wagenknecht DR, Biller J, Garg B. Henoch-Scholein purpura and stroke: antiphosphatidylethanolamine antibody in CSF and serum. Neurology 2000; 55:1379–1381
175. Gonzales-Portillo F, McIntyre JA, Wagenknecht DR, Williams LS, Bruno A, Biller J. Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc Dis 2001; 10:222–226
176. Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence or cause? Arch Pathol Lab Med 1993; 117:78–88
177. Gilman-Sachs A, Lubinski J, Beer AE, Brend S, Beaman KD. Patterns of antiphospholipid antibody specificities. J Clin Lab Immunol 1991; 35:83–88
178. Karmochkine M, Berard M, Piette JC, Cacoub P, Aillaud MF, Harle JR, Godeau P, Boffa MC, Harle JR. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993; 2:157–160
179. Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol 1992; 22:1–14
180. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, Alam Z, Carey JL. IgG anticardiolipin antibody titer 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28:1660–1665
181. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, Hughes GR. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheumat Dis 1988; 47:849–854
182. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94:476–484
183. Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME, Godbold JH. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999; 30:1561–1565
184. Metz LM, Edworthy S, Mydlarski R, Fritzler MJ. The frequency of phospholipid antibodies in an unselected stroke population. Can J Neurol Sci 1998; 25:64–69
185. D’Olhaberriague L, Levine SR, Salowich-Palm L, Tanne D, Sawaya KL, Aurora TK, Perry M, Day M, Spencer T, Schultz L. Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology 1998; 51:1376–1380
186. Camerlingo M, Casto L, Censori B, Drago G, Frigeni A, Ferraro B, Servalli MC, Radicce E, Mamoli A. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 1995; 92:69–71
187. Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994; 344:452–456
188. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997–1002
189. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339:451–453
190. Hess DC, Krauss J, Adams RJ, Nichols FT, Zhang D, Rountree HA. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 1991; 41:525–528
191. Chakravarty KK, Byron MA, Webley M, Durkin CJ, al Hillawi AH, Bodley R, Wozniak J. Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients with systemic lupus erythematosus. Q J Med 1991; 79:397–405
192. Montalban J, Codina A, Ordi J, Vilardell M, Khamashta MA, Hughes GR. Antiphospholipid antibodies in cerebral ischemia. Stroke 1991; 22:750–753
193. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40:1190–1196
194. Trimble M, Bell DA, Brien W, Hachinski V, O’Keefe B, McLay C, Black J. The antiphospholipid syndrome: prevalence among patients with stroke and transient ischemic attacks. Am J Med 1990; 88:593–597
195. Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 1985; 15:254–262
196. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682–698
197. Sontheimer RD. The anticardiolipin syndrome. A new way to slice an old pie, or a new pie to slice? Arch Dermatol 1987; 123:590–595
198. Manoussakis MN, Gharavi AE, Drosos AA, Kitridou RC, Moutsopoulos HM. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol 1987; 44:297–307
199. Harris EN, Gharavi AE, Hughes GR. Anti-phospholipid antibodies. Clin Rheumat Dis 1985; 11:591–609
200. Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G, Denman AM, Froude G, Hughes GR. Anticardiolipin antibodies: occurrence in Behcet’s syndrome. Ann Rheumat Dis 1984; 43:746–748
201. Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheumat Dis 1989; 48:362–367
202. Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998; 7(suppl 2):S67-S74
203. Levine SR, Brey RL. Antiphospholipid antibodies and ischemic cerebrovascular disease. Semin Neurol 1991; 11:329–338
204. Briley DP, Coull BM, Goodnight SH Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989; 25:221–227
205. Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GR. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984; 2:47–51
206. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, Hughes GR. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheumat Dis 1987; 46:605–611
207. Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 1987; 44:876–883
208. Hart RG, Miller VT, Coull BM, Bril V. Cerebral infarction associated with lupus anticoagulants—preliminary report. Stroke 1984; 15:114–118
209. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Neurology 1997; 48:91–94
210. Feldmann E, Levine SR. Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options. Ann Neurol 1995; 37(suppl 1):S114-S130
211. Tanne D, D’Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002; 21:93–99
212. Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology 1999; 31:142–147
213. Alving B. Update on recognition and management of patients with acquired or inherited hypercoagulability. Compr Ther 1998; 24:302–309
214. Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40:1181–1189
215. D’Alton JG, Preston DN, Bormanis J, Green MS, Kraag GR. Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke 1985; 16:512–514
216. Elias M, Eldor A. Thromboembolism in patients with the ’lupus’-type circulating anticoagulant. Arch Intern Med 1984; 144:510–515
217. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19:265–275
218. Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol 1995; 26:716–724
219. Anderson D, Bell D, Lodge R, Grant E. Recurrent cerebral ischemia and mitral valve vegetation in a patient with antiphospholipid antibodies. J Rheumatol 1987; 14:839–841
220. Asherson RA, Hughes GR. The expanding spectrum of Libman Sacks endocarditis: the role of antiphospholipid antibodies. Clin Exp Rheumatol 1989; 7:225–228
221. Levine SR, Langer SL, Albers JW, Welch KM. Sneddon’s syndrome: an antiphospholipid antibody syndrome? Neurology 1988; 38:798–800
222. Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 1965; 77:180–185
223. Bruyn RP, van der Veen JP, Donker AJ, Valk J, Wolters EC. Sneddon’s syndrome. Case report and literature review. J Neurol Sci 1987; 79:243–253
224. Coull BM, Bourdette DN, Goodnight SH Jr, Briley DP, Hart R. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 1987; 18:1107–1112
225. Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology 1990; 40:464–467
226. Chapman JA-K. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulatns. J Neurol Sci 2002; 203–204(C): 81–84
227. Rebollo M, Val JF, Garijo F, Quintana F, Berciano J. Livedo reticularis and cerebrovascular lesions (Sneddon’s syndrome). Clinical, radiological and pathological features in eight cases. Brain 1983; 106:965–979
228. Brandt KD, Lessell S, Cohen AS. Cerebral disorders of vision in systemic lupus erythematosus. Ann Intern Med 1975; 83:163–169
229. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13:486–489
230. Ingram SB, Goodnight SH Jr, Bennett RM. An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies: report of two cases. Arthritis Rheuma 1987; 30:1167–1172
231. Fulford KW, Catterall RD, Delhanty JJ, Doniach D, Kremer M. A collagen disorder of the nervous system presenting as multiple sclerosis. Brain 1972; 95:373–386
232. Tellez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RO, Davila-Maldonado L. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 2001; 10:851–856
233. Hasselaar P, Derksen RH, Blokzijl L, de Groot PG. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemostasis 1990; 63:169–173
234. Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res 1988; 51:267–281
235. Hess DC, Sheppard JC, Adams RJ. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke 1993; 24:994–999
236. D’Cruz DP, Houssiau FA, Ramirez G, Baguley E, McCutcheon J, Vianna J, Haga HJ, Swana GT, Khamashta MA, Taylor JC. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol 1991; 85:254–261
237. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10:455–460
238. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314:1193–1194
239. Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostasis 1988; 60:54–58
240. Carreras LO, Vermylen JG. “Lupus” anticoagulant and thrombosis—possible role of inhibition of prostacyclin formation. Thromb Haemostasis 1982; 48:38–40
241. Moreb J, Kitchens CS. Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases. Am J Med 1989; 87:207–210
242. Keeling DM, Wilson AJ, Mackie IJ, Isenberg DA, Machin SJ. Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993; 46:908–911
243. Cosgriff TM, Martin BA. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis & Rheum 1981; 24:94–96
244. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemostasis 1995; 74:1185–1190
245. Jacobs BSL. Antiphospholipid antibody syndrome. Cur Treat Options Neurol 2000; 2:449–458
246. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. Sickle cell disease: the neurological complications. Ann Neurol 2002; 51:543–552
247. Green MA, Noguchi CT, Keidan AJ, Marwah SS, Stuart J. Polymerization of sickle cell hemoglobin at arterial oxygen saturation impairs erythrocyte deformability. J Clin Invest 1988; 81:1669–1674
248. Grotta JC, Manner C, Pettigrew LC, Yatsu FM. Red blood cell disorders and stroke. Stroke 1986; 17:811–817
249. Keidan AJ, Sowter MC, Johnson CS, Noguchi CT, Girling AJ, Stevens SM, Stewart J. Effect of polymerization tendency on haematological, rheological and clinical parameters in sickle cell anaemia. Br J Haematol 1989; 71:551–557
250. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol 1990; 27:360–376
251. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol 1991; 28:213–219
252. Styles LA, Hoppe C, Klitz W, Vichinsky E, Lubin B, Trachtenberg E. Evidence for HLA- related susceptibility for stroke in children with sickle cell disease. Blood 2000; 95:3562–3567
253. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke 1978; 9:45–52
254. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 1986; 20:684–690
255. Wood DH. Cerebrovascular complications of sickle cell anemia. Stroke 1978; 9:73–75
256. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288–294
257. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vachinsky EP, Wang WC, Whethers DL, Younkin DP, Zimmerman RA, DeBaun MR. The Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001; 139:385–390
258. Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet 2001; 357:1656–1659
259. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, Figueroa R, Litaker M, Thompson W, Hess D. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992; 326:605–610
260. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5–11
261. Pavlakis SG, Bello J, Prohovnik I, Sutton M, Ince C, Mohr JP, Piomelli S, Hilal S, DeVivo DC. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol 1988; 23:125–130
262. Prohovnik I, Pavlakis SG, Piomelli S, Bello J, Mohr JP, Hilal S, DeVivo DC. Cerebral hyperemia, stroke, and transfusion in sickle cell disease. Neurology 1989; 39:344–348
263. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972; 287:846–849
264. Sultana C, Shen Y, Rattan V, Johnson C, Kalra VK. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 1998; 92:3924–3935
265. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96:2451–2459
266. Portnoy BA, Herion JC. Neurological manifestations in sickle-cell disease, with a review of the literature and emphasis on the prevalence of hemiplegia. Ann Intern Med 1972; 76:643–652